<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gao J</submitter><funding>Fundamental Research Funds for the Central Universities</funding><funding>Clinical Research Innovation Plan of Shanghai General Hospital</funding><funding>Shanghai Education Development Foundation and Shanghai Municipal Education Commission</funding><funding>National Natural Science Foundation of China</funding><funding>China Postdoctoral Science Foundation</funding><funding>Shanghai Rising-Star Program</funding><pagination>e2415384</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12097036</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(19)</volume><pubmed_abstract>Chordoma, a rare mesenchymal malignancy, exhibits a high tendency to postoperative recurrence and poor prognosis. To date, its tumorigenic regulatory mechanisms remain elusive, leading to a lack of effective therapeutic targets and drug sensitivity indicators. Here, via transcriptome and proteome analyses, RAB3B is unveiled as a prominent oncogenic regulator in chordoma, with high expression and enhancer-associated transcriptional activity. Notably, RAB3B ablation attenuated the chordoma cell stemness and malignant biological properties in vivo and in vitro. Through determining the RAB3B-mediated program in chordoma, it is identified that it enhanced the phosphorylation of S6 specifically at S235/236 and directly bound to S6. Mechanistically, RAB3B physically interacted with phosphorylase </pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1-Targeted Therapy.</pubmed_title><pmcid>PMC12097036</pmcid><funding_grant_id>22120220616</funding_grant_id><funding_grant_id>CTCCR-2021C09</funding_grant_id><funding_grant_id>21QA1407500</funding_grant_id><funding_grant_id>82472786</funding_grant_id><funding_grant_id>82173168</funding_grant_id><funding_grant_id>2021M702485</funding_grant_id><funding_grant_id>82073207</funding_grant_id><funding_grant_id>19CG20</funding_grant_id><funding_grant_id>82073155</funding_grant_id><pubmed_authors>Meng T</pubmed_authors><pubmed_authors>Song D</pubmed_authors><pubmed_authors>Gao J</pubmed_authors><pubmed_authors>Sun W</pubmed_authors><pubmed_authors>Chang Z</pubmed_authors><pubmed_authors>Huang R</pubmed_authors><pubmed_authors>Yin H</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Huang Z</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Xiao J</pubmed_authors><pubmed_authors>Song S</pubmed_authors><pubmed_authors>Lin J</pubmed_authors><pubmed_authors>Jin J</pubmed_authors></additional><is_claimable>false</is_claimable><name>RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1-Targeted Therapy.</name><description>Chordoma, a rare mesenchymal malignancy, exhibits a high tendency to postoperative recurrence and poor prognosis. To date, its tumorigenic regulatory mechanisms remain elusive, leading to a lack of effective therapeutic targets and drug sensitivity indicators. Here, via transcriptome and proteome analyses, RAB3B is unveiled as a prominent oncogenic regulator in chordoma, with high expression and enhancer-associated transcriptional activity. Notably, RAB3B ablation attenuated the chordoma cell stemness and malignant biological properties in vivo and in vitro. Through determining the RAB3B-mediated program in chordoma, it is identified that it enhanced the phosphorylation of S6 specifically at S235/236 and directly bound to S6. Mechanistically, RAB3B physically interacted with phosphorylase </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-06-01T22:21:30.342Z</modification><creation>2026-05-22T03:07:55.577Z</creation></dates><accession>S-EPMC12097036</accession><cross_references><pubmed>40135815</pubmed><doi>10.1002/advs.202415384</doi></cross_references></HashMap>